Clinical trials conducted outside of the United States are booming. Most FDA and EMA approvals involve at least one foreign clinical study, and many rely exclusively on foreign data. Trials conducted overseas and particularly in markets with notoriously low levels of transparency carry with them additional risks of bribery that can taint studies both legally and ethically. There are steps that companies can take to reduce these risks, while bolstering their compliance structure and improving their reputation.
[Read more...]
sending...